Press Release For Immediate Release

Glenmark announces approval and launch of Trandolapril & Verapamil Hydrochloride (HCl) Extended Release Tablets in the US

Mumbai, India February 26, 2015 –Glenmark Generics Inc., USA, the subsidiary of Glenmark Generics Limited today announced the U.S. market approval and introduction of Trandolapril & Verapamil Hydrochloride (HCl) Extended Release Tablets, the generic equivalent of AbbVie, Inc.'s TARKA®.

TARKA® is indicated for the treatment of hypertension. According to IMS Health sales data for the 12 month period ending December 2014, TARKA® achieved annual sales of approximately USD 23.5 million.

Glenmark will commence distribution of Trandolapril & Verapamil HCl Tablets immediately, which will be available in 1mg/240mg, 2mg/180mg, 2mg/240mg and 4mg/240mg strengths.

Glenmark's current portfolio consists of 95 products authorized for distribution in the U.S. marketplace and 74 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics Limited

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984
Email: corpcomm@glenmarkpharma.com